Enterprise Value
881.7M
Cash
357.3M
Avg Qtr Burn
-22.31M
Short % of Float
19.72%
Insider Ownership
22.79%
Institutional Own.
85.44%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Approved Update | |
AMX0035 Details Progressive supranuclear palsy | Phase 3 Initiation | |
AMX0035 Details Wolfram syndrome | Phase 2 Data readout | |
AMX0035 Details Alzheimer's disease | Phase 2 Update |